{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T10:14:31Z","timestamp":1774692871715,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Gastroenterol"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s12664-020-01131-x","type":"journal-article","created":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T03:03:26Z","timestamp":1616814206000},"page":"41-49","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Efficacy of combining pentoxiphylline and vitamin E versus vitamin E alone in non-alcoholic steatohepatitis\u2014\u00a0A randomized pilot study"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7239-0293","authenticated-orcid":false,"given":"Chandan Kumar","family":"Kedarisetty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankit","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guresh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archana","family":"Rastogi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chhagan","family":"Bihari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiv Kumar","family":"Sarin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,27]]},"reference":[{"key":"1131_CR1","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cld.2015.10.001","volume":"20","author":"M Sayiner","year":"2016","unstructured":"Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the United States and the rest of the world. Clin Liver Dis. 2016;20:205\u201314.","journal-title":"Clin Liver Dis"},{"issue":"1","key":"1131_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/hep.29466","volume":"67","author":"C Estes","year":"2018","unstructured":"Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123-33.\u00a0","journal-title":"Hepatology"},{"key":"1131_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12664-020-01018-x","volume":"39","author":"SW Wong","year":"2020","unstructured":"Wong SW, Chan WK. Epidemiology of non-alcoholic fatty liver disease in Asia. Indian J Gastroenterol. 2020;39:1\u20138.","journal-title":"Indian J Gastroenterol"},{"key":"1131_CR4","doi-asserted-by":"crossref","unstructured":"Duseja A, Sharma BK, Kumar A, et al. Nonalcoholic fatty liver in a developing country is responsible for significant liver disease. Hepatology. 2010;52:2248\u20139.","DOI":"10.1002\/hep.23838"},{"key":"1131_CR5","doi-asserted-by":"crossref","unstructured":"Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction- associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202\u20139.","DOI":"10.1016\/j.jhep.2020.07.045"},{"key":"1131_CR6","doi-asserted-by":"crossref","unstructured":"Bhala N, Angulo P, Van der Poorten D, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology. 2011;54:1208\u201316.","DOI":"10.1002\/hep.24491"},{"issue":"1","key":"1131_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1872-034X.2011.00872.x","volume":"42","author":"E Hashimoto","year":"2012","unstructured":"Hashimoto E, Tokushige K. Hepatocellular carcinoma in nonalcoholic steatohepatitis: growing evidence of an epidemic? Hepatol Res. 2012;42:1\u201314.","journal-title":"Hepatol Res"},{"issue":"14","key":"1131_CR8","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1056\/NEJMra0912063","volume":"363","author":"G Targher","year":"2010","unstructured":"Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic steatohepatitis. N Engl J Med. 2010;363:1341\u201350.","journal-title":"N Engl J Med"},{"key":"1131_CR9","doi-asserted-by":"crossref","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005\u201323.","DOI":"10.1002\/hep.25762"},{"key":"1131_CR10","doi-asserted-by":"crossref","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328\u201357.","DOI":"10.1002\/hep.29367"},{"key":"1131_CR11","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1111\/j.1478-3231.2011.02604.x","volume":"31","author":"AK Singhal","year":"2011","unstructured":"Singhal AK, Jampana SC, Weinman SA. Antioxidants as therapeutic targets for liver disease. Liver Int. 2011;31:1432\u201348.","journal-title":"Liver Int"},{"key":"1131_CR12","doi-asserted-by":"crossref","unstructured":"Sanyal AJ, Chalasani N, Kowdley KV, et al. NASH CRN. Pioglitazone, vitamin E, or placebo for non-alcoholic steatohepatitis. N Engl J Med. 2010;362:1675\u201385.","DOI":"10.1056\/NEJMoa0907929"},{"key":"1131_CR13","unstructured":"Neuner P, Klosner G, Schauer E, et al. Pentoxiphylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumor necrosis factor alpha by human peripheral blood mononuclear cells. Immunology. 1994;83:262\u20137."},{"key":"1131_CR14","doi-asserted-by":"crossref","unstructured":"Satapathy SK, Sakhuja P, Malhotra V, Sharma BC, Sarin SK. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 2007;22:634\u20138.\u00a0","DOI":"10.1111\/j.1440-1746.2006.04756.x"},{"key":"1131_CR15","doi-asserted-by":"crossref","unstructured":"Kleiner DE, Brunt EM, Van Matta M, et al. Design and validation of a histologic scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313\u201321.","DOI":"10.1002\/hep.20701"},{"issue":"3","key":"1131_CR16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.5114\/ceh.2018.78120","volume":"4","author":"C Lucas","year":"2018","unstructured":"Lucas C, Lucas G, Lucas N, Krzowska-Firych J, Tomasiewicz K. A systematic review of the present and future of non-alcoholic fatty liver disease. Clin Exp Hepatol. 2018;4:165\u201374.\u00a0","journal-title":"Clin Exp Hepatol"},{"issue":"4","key":"1131_CR17","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","volume":"67","author":"M Romero-G\u00f3mez","year":"2017","unstructured":"Romero-G\u00f3mez M, Zelber-Sagi S, Trenell M. Treatment of NASH with diet, physical activity and exercise. J Hepatol. 2017;67:829\u201346.","journal-title":"J Hepatol"},{"key":"1131_CR18","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/j.1467-789X.2009.00657.x","volume":"11","author":"G Musso","year":"2010","unstructured":"Musso G, Gambino R, Cassader M. Nonalcoholic fatty liver disease from pathogenesis to management. An update. Obes Rev. 2010;11:430\u201345.","journal-title":"Obes Rev"},{"key":"1131_CR19","doi-asserted-by":"crossref","unstructured":"Sorrentino P, Terracciano L, D'Angelo S, Ferbo U, Bracigliano A, Vecchione R. Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and hypertension. Am J Gastroenterol. 2010;105:336-44.\u00a0","DOI":"10.1038\/ajg.2009.587"},{"key":"1131_CR20","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jhep.2019.04.019","volume":"71","author":"ME Rinella","year":"2019","unstructured":"Rinella ME, Tacke F, Sanyal AJ, Anstee QM. Report on AASLD\/ EASL joint workshop on clinical trial endpoints in NAFLD. J Hepatol. 2019;71:823\u201333.","journal-title":"J Hepatol"},{"key":"1131_CR21","doi-asserted-by":"crossref","unstructured":"Wong VW, Verginol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness in nonalcoholic fatty liver disease. Hepatology. 2010;51:454\u201362.","DOI":"10.1002\/hep.23312"},{"key":"1131_CR22","doi-asserted-by":"crossref","unstructured":"Duman DG, Ozdeimer F, Birben E, et al. Effects of pentoxiphylline on TNF alpha production by peripheral blood mononuclear cells in patients with nonalcoholic steatohepatitis. Dig Dis Sci. 2007;52:2520\u20134.","DOI":"10.1007\/s10620-006-9723-y"},{"key":"1131_CR23","doi-asserted-by":"crossref","unstructured":"Zein CO, Yerian LM, Gogate P, et al. Pentoxyphylline improves non-alcoholic steatohepatitis \u2013 a randomized placebo-controlled trial. Hepatology. 2011;54:1610\u20139.","DOI":"10.1002\/hep.24544"},{"key":"1131_CR24","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1111\/j.1572-0241.2004.40064.x","volume":"99","author":"LA Adams","year":"2004","unstructured":"Adams LA, Zein CO, Angulo P, Lindor KD. A pilot trial of pentoxiphylline in nonalcoholic steatohepatitis. Am J Gastroenterol. 2004;99:2365\u20138.","journal-title":"Am J Gastroenterol"},{"key":"1131_CR25","doi-asserted-by":"crossref","unstructured":"Zein C, Lopez R, Fu X, et al. Pentoxiphylline decreases oxidized lipid products in non-alcoholic steatohepatitis. Hepatology. 2012;56:1291\u20139.","DOI":"10.1002\/hep.25778"},{"issue":"6","key":"1131_CR26","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1097\/MEG.0000000000000068","volume":"26","author":"T Zeng","year":"2014","unstructured":"Zeng T, Zhang CL, Zhao XL, Xie KQ. Pentoxiphylline for the treatment of non-alcoholic fatty liver disease: meta-analysis of randomized double-blind, placebo-controlled trials. Eur J Gastroenterol Hepatol. 2014;26:648\u201353.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1131_CR27","doi-asserted-by":"crossref","unstructured":"Day CP, James OF. Steatohepatitis: a tale of two hits. Gastroenterology. 1998;114:842\u20135.","DOI":"10.1016\/S0016-5085(98)70599-2"},{"key":"1131_CR28","doi-asserted-by":"crossref","unstructured":"Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305:1659\u201368.","DOI":"10.1001\/jama.2011.520"},{"key":"1131_CR29","first-page":"75","volume":"8","author":"BA Banini","year":"2016","unstructured":"Banini BA, Sanyal AJ. Nonalcoholic fatty liver disease: epidemiology, pathogenesis, natural history and current treatment options. Clin Med Insights Ther. 2016;8:75\u201384.","journal-title":"Clin Med Insights Ther"},{"key":"1131_CR30","doi-asserted-by":"crossref","unstructured":"Patel K, Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep. 2020;2:100067.","DOI":"10.1016\/j.jhepr.2020.100067"},{"key":"1131_CR31","doi-asserted-by":"crossref","unstructured":"Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre randomised, placebo controlled phase 3 trial. Lancet. 2019;394:2184\u201396.","DOI":"10.1016\/S0140-6736(19)33041-7"},{"key":"1131_CR32","doi-asserted-by":"crossref","unstructured":"Schiffman M, Freilich B, Vuppalanchi R, et al. Randomised clinical trial: emricasan versus placebo significantly reduced ALT and caspase 3\/7 activation in subjects with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2019;49:64\u201373.","DOI":"10.1111\/apt.15030"}],"container-title":["Indian Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-020-01131-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12664-020-01131-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-020-01131-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T04:56:16Z","timestamp":1698123376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12664-020-01131-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["1131"],"URL":"https:\/\/doi.org\/10.1007\/s12664-020-01131-x","relation":{},"ISSN":["0254-8860","0975-0711"],"issn-type":[{"value":"0254-8860","type":"print"},{"value":"0975-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"15 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"CKK, AB, GK, AR, CB, MK, and SKS\u00a0 declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was performed conforming to the Helsinki declaration of 1975, as revised in 2000 and 2008 concerning human and animal rights, and the authors followed the policy concerning informed consent as shown on Springer.com. This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Ethics Committee of Institute of Liver and Biliary Sciences, New Delhi.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"The authors are solely responsible for the data and the contents of the paper. In no way, the Honorary Editor-in-Chief, Editorial Board Members, the Indian Society of Gastroenterology, or the printer\/publishers are responsible for the results\/findings and content of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}